An effective method for improving outcomes in patients with a fertilization defect

Hye Jin Yoon¹, Hyung Jun Kim¹, In Hee Bae¹, Soo Jin Chae¹, San Hyun Yoon², Won Don Lee¹, Jin Ho Lim¹

¹Maria Reproductive Center, Department of Obstetrics and Gynecology, Maria Fertility Hospital, Seoul; ²Maria Research Center, Seoul, Korea

The effect of artificial oocyte activation (AOA) with a calcium ionophore on intracytoplasmic morphologically selected sperm injection (IMSI) was examined in patients with histories of repeated failed implantation attempts. Four singleton pregnancies and one twin pregnancy were obtained after embryos transfer (5/14, 35.7%). Therefore, AOA combined with IMSI can be considered an option for cycles with a fertilization defect and recurrent implantation failures.

Keywords: Artificial oocyte activation; Intracytoplasmic morphologically selected sperm injection; Recurrent implantation failures

Recurrent implantation failure refers to failures of embryo implantation following at least two embryo transfers. An appropriate application of fertilization methods for individual patients is a crucial step in conception via the use of artificial reproductive technologies (ARTs). In particular, intracytoplasmic sperm injection (ICSI) has been commonly used as a fertilization method in ART cycles to overcome severe male infertility. However, post-ICSI fertilization failure can be attributed to a lack of oocyte activation, and the assistance of oocyte activation with a calcium ionophore following ICSI has been proposed to solve this problem [1]. Following treatment with calcium ionophore, the number of Ca²⁺ ions in the oocyte cell membrane increases and the extracellular Ca²⁺ ions flow into the oocyte. Finally, the calcium ionophore induces the Ca²⁺ concentration peak.

It is clear that performing ICSI with abnormal sperm can potentially induce paternal effects and that chromosomally abnormal sperm have an adverse effect on the outcomes [2]. Intracytoplasmic morphologically selected sperm injection (IMSI) represents an alternative for patients who have experienced repeated failed ICSI cycles. Further, the fine morphological state of the sperm nucleus has been shown to be an important factor in achieving pregnancy after ICSI [3].

This study was designed to analyze whether artificial oocyte activation (AOA) was associated with the results of the IMSI treatment in patients with zero or low fertilization rates despite AOA being performed after ICSI to overcome the difficulties of the fertilization procedure.

The AOs combined with IMSIs were performed between January 2012 and July 2013. This retrospective study was approved by the Institutional Review Board of Ethics and Research (2013-008). A total of 14 patients (35.57 ± 3.90 years) who underwent IMSI–AOA were included in this study. The criteria for inclusion in this study were as follows: 1) male-factor-mediated infertility with oligo-astheno-teratozoospermia (OAT); 2) an experience of a zero or low (< 35%) fertilization rate following ICSI–AOA; 3) a day-3 follicular stimulating hormone level below 10 IU/L and an AMH above 1 ng/mL; and 4) a body mass index of between 19 kg/m² and 25 kg/m².

All patients underwent standard controlled ovarian stimulation (COS) via the administration of gonadotropins by using a long stimulation with agonist cycles. The zygotes were cultured in a COOK medium (Brisbane, Australia). Three days after the insemination, the embryos were transferred into the uterus of the female patient.

Serum HCG levels were measured 14 days after the oocytes were transplanted back into the uterus, and clinical pregnancies were confirmed by vaginal ultrasound scans that revealed the presence of an intrauterine gestational sac 6–7 weeks after embryo transfer.
Normal spermatozoa were confirmed when the shapes of the nuclei were smooth and symmetrical with an ovular configuration, and the average lengths and widths were 4.75 ± 0.28 µm and 3.28 ± 0.20 µm, respectively [4]. Additionally, the selected nuclei contained no more than one vacuole that comprised less than 4% of the nuclear area (Figure 1). All motile spermatozoa were analyzed using a high-magnification (6,000 ×) microscope (TE 2000 U, Nikon, Tokyo, Japan) with 60 × air objectives and modulation contrast illumination (RI IMSI, RI, Falmouth, Cornwall, UK). After the selection of normal spermatozoa by high magnification, the oocytes underwent ICSI within 2 hours of oocyte denudation. Fertilization was confirmed 17–19 hours after insemination.

The calcium ionophore A23187 (Sigma Chemical, Sigma, St Louis, MO, USA) was used for AOA, as previously described [5]. The final solution (10 µmol/L) was prepared prior to ICSI or IMSI. Thirty minutes after insemination, the oocytes were exposed to the calcium ionophore for 30 minutes at 37°C in 6% CO₂ and 5% O₂. AOA with a calcium ionophore was performed in 14 IMSI cycles with histories of zero or low fertilization rates in the previous AOA following ICSI (Table 1). The average age (± SD) of the females was 35.57 ± 3.90, and the mean number of IVF experiences per patient was 2.50 ± 1.09. The average number of oocytes retrieved was 7.93, and on average, 5.38 mature oocytes were used for ICSI. The fertilization rate was 62.9% (4.71 ± 2.30), and the mean number (± SD) of embryos that developed normally on the day after the confirmation of fertilization was 4.57 ± 2.34. A mean of 2.71 ± 0.73 embryos per patient were transferred. After embryo transfer, the clinical pregnancy rate was 35.7%, and four singleton pregnancies and one twin pregnancy were obtained. These five pregnancies produced six healthy babies.

In a preliminary study, increased fertilization rates and significantly higher clinical pregnancy and implantation rates were achieved using AOA following ICSI compared with the previous treatment with standard ICSI in a group of patients who had experienced total fertilization failure or low fertilization rates (< 50%) in their previous ICSI cycles. Furthermore, 38 healthy babies were delivered from 185 ICSI cycles by using AOA with a calcium ion [5]. These results support the safety of AOA for ICSI cycles in patients with previous experiences of zero or low fertilization rates.

However, although these results indicate that the application of AOA for ICSI cycles in which defects in the fertilization procedure occurred in the previous ICSI cycles is clinical beneficial, the performance of AOA does not always result in appropriate fertilization. There are important aspects related to an appropriate selection of fine spermatozoa and oocyte activation. Therefore, it is crucial to establish a novel technique that can overcome difficulties in such cycles prior to subsequent IVF treatments.

Table 1. Clinical outcomes of artificial oocyte activation following IMSI–AOA

| Outcomes                        | IMSI–AOA |
|---------------------------------|----------|
| Embryo transfer cycle           | 14       |
| Female age (yr)                 | 35.57 ± 3.90 |
| Previous ART cycle              | 2.50 ± 1.09 |
| Retrieved oocytes               | 7.93 ± 4.14 |
| Mature oocytes                  | 5.38 ± 3.69 |
| Fertilized embryos              | 4.71 ± 2.30 (59.5%) |
| Cleavage embryos on day 2       | 4.57 ± 2.34 |
| High-quality embryos on day 3    | 1.33 ± 1.07 |
| Transferred embryos             | 2.71 ± 0.73 |
| Clinical pregnancy              | 35.7% (5/14) |
| Implantation                    | 15.8% (6/38) |
| No. of live births              | 5        |
| Miscarriage                     | 0        |

Values are presented as mean ± standard deviation or rates. IMSI, intracytoplasmic morphologically selected sperm injection; AOA, artificial oocyte activation; Clinical pregnancy, presence of a gestational sac/TRANSFERRED CYCLE; implantation, number of gestational sacs/TRANSFERRED EMBRYOS.

Figure 1. Spermatozoa observed under high magnification (6,000 ×) microscopy with a 60 × air objective with modulation contrast. (A) A normal spermatozoon, (B) a spermatozoon with two large vacuoles (arrow), and (C) a spermatozoon with a large vacuole (arrow).
defects of the head, neck, and tail. However, this technique is of limited utility for investigating nuclear vacuoles in the sperm head. A significant correlation between the incidence of morphologically normal spermatozoa without vacuoles in the head [6] and higher fertilization using IMSI has been reported [4,7]. The significant benefits of the application of IMSI have been demonstrated to result in higher ongoing-pregnancy rates among patients with at least two prior implantation failures [8] and among all patients with severe OAT male-factor infertility [9].

This center began the application of IMSI for patients who failed IVF treatment at least twice following fertilization by ICSI. There were no statistically significant differences in the fertilization rate, but the clinical pregnancy rate and implantation rate were higher than those of the previous ICSI cycles in the same couples [10]. Calcium ionophores have been used at this center to overcome fertilization failure in cases with histories of low fertilization rates after ICSI. Although the oocytes were activated artificially after ICSI, some cycles did not exhibit sufficient fertilization rates. To rescue such cycles, IMSI was applied in combination with AOA following the acquisition of written informed consent to share the outcomes for research purposes from all the patients.

The data from this combination of IMSI and AOA indicate that sperm selection under high magnification might serve a protective role that enables one to avoid the detrimental effects of inadequate sperm. However, this study has a limitation: The number of patients examined in the study of the relationships between AOA combined with IMSI and the clinical outcomes was small. Therefore, a well-designed large-scale study is needed.

In conclusion, AOA with a calcium ionophore combined with IMSI might be a good technique to improve the clinical outcomes of couples with histories of zero or low fertilization rates following ICSI–AOA. This option could be particularly relevant to couples with histories of repeated implantation failures.

**Conflict of interest**

No potential conflict of interest relevant to this article was reported.

**References**

1. Rybouchkin AV, Van der Straeten F, Quatacker J, De Sutter P, Dhont M. Fertilization and pregnancy after assisted oocyte activation and intracytoplasmic sperm injection in a case of round-headed sperm associated with deficient oocyte activation capacity. Fertil Steril 1997;68:1144-7.
2. Burrello N, Vicari E, Shin P, Agarwal A, De Palma A, Grazioso C, et al. Lower sperm aneuploidy frequency is associated with high pregnancy rates in ICSI programmes. Hum Reprod 2003;18:1371-6.
3. Bartoov B, Berkovitz A, Eltes F, Kogosovsky A, Yagoda A, Lederman H, et al. Pregnancy rates are higher with intracytoplasmic morphologically selected sperm injection than with conventional intracytoplasmic injection. Fertil Steril 2003;80:1413-9.
4. Bartoov B, Berkovitz A, Eltes F, Kogosovsky A, Menezes Y, Barak Y. Real-time fine morphology of motile human sperm cells is associated with IVF-ICSI outcome. J Androl 2002;23:1-8.
5. Yoon HJ, Bae IH, Kim HJ, Jang JM, Hur YS, Kim HK, et al. Analysis of clinical outcomes with respect to spermatozoan origin after artificial oocyte activation with a calcium ionophore. J Assist Reprod Genet 2013;30:1569-75.
6. Berkovitz A, Eltes F, Ellenbogen A, Peer S, Feldberg D, Bartoov B. Does the presence of nuclear vacuoles in human sperm selected for ICSI affect pregnancy outcome? Hum Reprod 2006;21:1787-90.
7. Berkovitz A, Eltes F, Yaari S, Katz N, Barr I, Fishman A, et al. The morphological normalcy of the sperm nucleus and pregnancy rate of intracytoplasmic injection with morphologically selected sperm. Hum Reprod 2005;20:185-90.
8. Oliveira JB, Cavagna M, Petersen CG, Mauri AL, Massaro FC, Silva LF, et al. Pregnancy outcomes in women with repeated implantation failures after intracytoplasmic morphologically selected sperm injection (IMSI). Reprod Biol Endocrinol 2011;9:99.
9. Antinori M, Licata E, Dani G, Cerusico F, Versaci C, d’Angelo D, et al. Intracytoplasmic morphologically selected sperm injection: a prospective randomized trial. Reprod Biomed Online 2008;16:835-41.
10. Kim HJ, Yoon HJ, Jang JM, Oh HS, Lee YJ, Lee WD, et al. Comparison between intracytoplasmic sperm injection and intracytoplasmic morphologically selected sperm injection in oligo-astheno-teratozoospermia patients. Clin Exp Reprod Med 2014;41:9-14.